You are here » Home » Companies » Company Overview » Fermenta Biotech Ltd

Fermenta Biotech Ltd.

BSE: 506414 Sector: Health care
NSE: N.A. ISIN Code: INE225B01021
BSE 00:00 | 14 Oct 304.85 -6.25
(-2.01%)
OPEN

311.00

HIGH

311.00

LOW

301.15

NSE 05:30 | 01 Jan Fermenta Biotech Ltd
OPEN 311.00
PREVIOUS CLOSE 311.10
VOLUME 24464
52-Week high 373.00
52-Week low 249.00
P/E 18.52
Mkt Cap.(Rs cr) 897
Buy Price 0.00
Buy Qty 0.00
Sell Price 0.00
Sell Qty 0.00
OPEN 311.00
CLOSE 311.10
VOLUME 24464
52-Week high 373.00
52-Week low 249.00
P/E 18.52
Mkt Cap.(Rs cr) 897
Buy Price 0.00
Buy Qty 0.00
Sell Price 0.00
Sell Qty 0.00

Fermenta Biotech Ltd. (FERMENTABIOTEC) - Chairman Speech

Company chairman speech

What we achieved in the area of Vitamin D in the last decade is what we seek to achievein the nutraceuticals space across the next ten years.

The time has come to add a prefix: the word ‘fortified'.

The increasing relevance of this word is derived from the fact that the world faces alarge economic burden arising from malnutrition. India is ranked an alarming 102 out of117 countries in the Global Hunger Index (GHI) a reflection of chronic and acuteundernutrition. Malnutrition is the most common cause of immunodeficiency withmicronutrient deficiency and protein-energy malnutrition being at the core of thechallenge.

The trinity of dietary diversification food fortification and supplementation arerequired for overcoming micronutrient deficiency. Fermenta's products enjoy extensiveapplications across supplementation and fortification which play a large health role.Fortification of staple foods is being widely acknowledged as one of the most effectiveways for combating micronutrient deficiency across age groups. The addition ofmicronutrient premix to food to enhance the nutritional quality is a scientificallyproven cost-effective scalable and sustainable solution. In the last few years therehas been a greater impetus to the fortification movement. Forward-looking governments arerecognising that the cost of proactive food fortification is but a fraction of the costarising out of reactive remedial action which could include the cost of medicines andhospitalisation. Following discipline to make this happen. We are competently placed toprovide the complete basket of products (either manufactured within or outsourced) thatmakes a single-point solution provider. What we have going for our business case is thatwe are prudently borrowing we have a widening global presence through subsidiaries ourmanufacturing discipline has been validated by demanding global customers andcertifications and we have demonstrated the capacity to build and sustain eco-systemrelationships across the long-term.

The result is that we are not just engaged in growing our business from quarter toquarter; we are engaged in capitalising on a structural shift with a fundamental change inthe way we see our business across the coming decade. We expect to address this sizableopportunity with a prudent mix of debt and internal accruals which are intended toenhance value in the hands of all those who own shares in our Company.

Mr. Sanjay Buch
Chairman

.